AI, China, And Biotech Investing With SR One's Simeon George, M.D.
Source: Life Science Leader
On this week's episode of the Business of Biotech, Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets, and the good and bad signs that emerge during diligence. Simeon also discusses a new report published by SR One on how AI and China are changing the strategy and playbook for new drug creation.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Get in touch with guest and topic suggestions: ben.comer@lifescienceconnect.com
Find Ben Comer on LinkedIn https://www.linkedin.com/in/bencomer/
Find the Business of Biotech wherever you get your podcasts.